Search results
Showing 466 to 480 of 710 results for end of life care
Evidence-based recommendations on selpercatinib (Retsevmo) for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over.
Evidence-based recommendations on ciclosporin (Ikervis) for dry eye disease in adults that has not improved despite treatment with artificial tears.
Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating macular oedema following retinal vein occlusion in adults.
Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments in adults.
Evidence-based recommendations on ranibizumab (Lucentis) for treating visual impairment caused by macular oedema secondary to retinal vein occlusion in adults.
Dupilumab for treating severe asthma with type 2 inflammation (TA751)
Evidence-based recommendations on dupilumab (Dupixent) for treating severe asthma with type 2 inflammation that is inadequately controlled in people 12 years and over.
This guideline covers diagnosis and management of thyroid cancer in people aged 16 and over. It aims to reduce variation in practice and increase the quality of care and survival for people with thyroid cancer.
Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580)
Evidence-based recommendations on enzalutamide (Xtandi) for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults.
Community engagement: improving health and wellbeing and reducing health inequalities (NG44)
This guideline covers community engagement approaches to reduce health inequalities, ensure health and wellbeing initiatives are effective and help local authorities and health bodies meet their statutory obligations.
Human growth hormone (somatropin) in adults with growth hormone deficiency (TA64)
Evidence-based recommendations on human growth hormone (somatropin; Genotropin, Humatrope, Norditropin, NutropinAq, Omnitrope, Saizen, Zomacton) for treating growth hormone deficiency in adults.
This guideline covers assessment and early management of head injury in babies, children, young people and adults. It aims to ensure that people have the right care for the severity of their head injury, including direct referral to specialist care if needed.
NICE has developed a medtech innovation briefing (MIB) on CentriMag for heart failure .
This guideline covers managing spasticity and co-existing motor disorders and their early musculoskeletal complications in children and young people (from birth up to their 19th birthday) with non-progressive brain disorders. It aims to reduce variation in practice and help healthcare professionals to select and use appropriate treatments.
Evidence-based recommendations on darolutamide (Nubeqa) with androgen deprivation therapy and docetaxel for hormone-sensitive metastatic prostate cancer in adults.
Evidence-based recommendations on entecavir for treating chronic hepatitis B in adults.